Celebrex and HO Study | Clinical Trial | StuddyBuddy@endsection Celebrex and HO Study
Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore!   Learn More →
← Back to all trials
Enrolling By Invitation NCT05648916

Celebrex and HO Study

Conditions: Heterotopic Ossification

Sex: All
Enrollment: 200
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Location: Canada

Summary

The primary goal of this observational study is to demonstrate the incidence of heterotopic ossification (HO) in patients with cementless total hip joint replacement surgery over time and secondly, demonstrate the relationship between celecoxib and HO formation. Lastly, investigators will examine the relationship between HO and patient-reported outcome measures (PROMs).

Eligibility Criteria

Inclusion Criteria:All primary total hip replacements with Cementless Tri-lock BPS (Depuy, Warsaw, IN) with minimum 2 years follow up.Exclusion Criteria:Revision surgeryInfectionsOther implants

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT05648916). StuddyBuddy aggregates publicly available trial information.